Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 1
1990 1
1994 3
1995 2
1996 2
1997 1
1998 4
1999 2
2000 2
2002 1
2003 1
2004 3
2005 2
2006 4
2007 7
2008 12
2009 6
2010 6
2011 10
2012 3
2013 5
2014 13
2015 12
2016 8
2017 6
2018 6
2019 7
2020 5
2021 6
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for haemate p coagulation factor viii willebrand factor
Your search for hfemate-p-coagulation-factor-viii-willebrand-factor retrieved no results
The history of haemophilia - a short review.
Schramm W. Schramm W. Thromb Res. 2014 Nov;134 Suppl 1:S4-9. doi: 10.1016/j.thromres.2013.10.020. Epub 2014 Feb 7. Thromb Res. 2014. PMID: 24513149 Review.
A turning point in the history of haemophilia came in the middle of the 20th century when researchers identified an "antihaemophilic globulin" that could reduce the clotting time in haemophilic blood, thereby paving the way for the introduction of cryoprecipitate and the first cl …
A turning point in the history of haemophilia came in the middle of the 20th century when researchers identified an "antihaemophilic globuli …
Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.
Carter NJ, Scott LJ. Carter NJ, et al. Drugs. 2007;67(10):1513-9. doi: 10.2165/00003495-200767100-00009. Drugs. 2007. PMID: 17600395 Review.
Haemate P/Humate-P is a pasteurised human plasma-derived concentrate containing coagulation factor VIII and a near-normal spectrum of von Willebrand factor multimers, including high-molecular weight multimers, for intravenous use i …
Haemate P/Humate-P is a pasteurised human plasma-derived concentrate containing coagulation factor VIII a …
Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Auerswald G, Kreuz W. Auerswald G, et al. Haemophilia. 2008 Nov;14 Suppl 5:39-46. doi: 10.1111/j.1365-2516.2008.01850.x. Haemophilia. 2008. PMID: 18786009 Review.
Desmopressin (DDAVP) and von Willebrand factor/factor VIII (VWF/FVIII) concentrates are the principal treatments. Haemate P/Humate-P is an intermediate-purity VWF/FVIII concentrate with extensive clinical experience in VWD. ...
Desmopressin (DDAVP) and von Willebrand factor/factor VIII (VWF/FVIII) concentrates are the principal treatments …
von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery.
Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM; HAEMATE P Surgical Study Group. Lethagen S, et al. J Thromb Haemost. 2007 Jul;5(7):1420-30. doi: 10.1111/j.1538-7836.2007.02588.x. Epub 2007 Apr 16. J Thromb Haemost. 2007. PMID: 17439628 Free article. Clinical Trial.
OBJECTIVES: To determine the feasibility of dosing Haemate P VWF/factor VIII (FVIII) concentrate based on pharmacokinetics (PK) in the management of surgical subjects with VWD. ...Selection of Haemate P loading dose on the basis of VWF PK …
OBJECTIVES: To determine the feasibility of dosing Haemate P VWF/factor VIII (FVIII) concentrate based on pharma …
Haemate P/Humate-P: a systematic review.
Berntorp E. Berntorp E. Thromb Res. 2009 Nov;124 Suppl 1:S11-4. doi: 10.1016/S0049-3848(09)70152-5. Thromb Res. 2009. PMID: 19944255 Review.
Haemate P/Humate-P, the first plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII)-containing concentrate that was pasteurized to reduce the risk of virus infection, was developed in the 1970s and approved for use in Germany in …
Haemate P/Humate-P, the first plasma-derived von Willebrand factor (VWF)/factor VIII (FVIII)-conta …
Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
Schramm W. Schramm W. Haemophilia. 2008 Nov;14 Suppl 5:3-10. doi: 10.1111/j.1365-2516.2008.01847.x. Haemophilia. 2008. PMID: 18786006
One of the key milestones in the evolution of the treatment of VWD was the development of Haemate P/Humate-P (CSL Behring) - the first virus-inactivated factor VIII plasma product. ...This article provides an historical overview of the early landmark e …
One of the key milestones in the evolution of the treatment of VWD was the development of Haemate P/Humate-P (CSL Behring) - t …
Clinical use of Haemate P in von Willebrand disease: a 25-year retrospective observational study.
Miesbach W, Krekeler S, Wolf Z, Seifried E. Miesbach W, et al. Thromb Res. 2015 Mar;135(3):479-84. doi: 10.1016/j.thromres.2014.12.017. Epub 2014 Dec 27. Thromb Res. 2015. PMID: 25595881
INTRODUCTION: von Willebrand disease (VWD) is caused by dysfunction or diminished levels of von Willebrand factor (VWF). ...A single-centre, retrospective observational study over a period of up to 25 years was conducted to evaluate the effectiveness and safe …
INTRODUCTION: von Willebrand disease (VWD) is caused by dysfunction or diminished levels of von Willebrand factor (VWF) …
Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH. Michiels JJ, et al. Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30. doi: 10.1097/00001721-200406000-00006. Blood Coagul Fibrinolysis. 2004. PMID: 15166918 Clinical Trial.
The parameters to diagnose von Willebrand disease (vWD) include factor VIII coagulant activity (FVIII:C), von Willebrand factor antigen (vWF:Ag), von Willebrand factor ristocetin cofactor activity (vWF:RCo), and von Willebrand …
The parameters to diagnose von Willebrand disease (vWD) include factor VIII coagulant activity (FVIII:C), von Willeb …
Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA; Association of Hemophilia Clinic Directors of Canada. Lillicrap D, et al. Thromb Haemost. 2002 Feb;87(2):224-30. Thromb Haemost. 2002. PMID: 11858481
The present study was initiated to evaluate the safety and efficacy of Haemate-P (Humate-P in North America) (anti-hemophilic FVIII/VWF complex [human] dried, pasteurized) dosed in ristocetin cofactor units (VWF:RCo) in the treatment of von Willebrand disease …
The present study was initiated to evaluate the safety and efficacy of Haemate-P (Humate-P in North America) (anti-hemophilic …
Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA. Batlle J, et al. Blood Coagul Fibrinolysis. 2009 Mar;20(2):89-100. doi: 10.1097/MBC.0b013e3283254570. Blood Coagul Fibrinolysis. 2009. PMID: 19786936 Review.
Therapy for von Willebrand disease (VWD) aims to restore the hemostatic function conferred by von Willebrand factor (VWF), which facilitates platelet adhesion and aggregation, and serves to increase potentially low coagulation factor VIII …
Therapy for von Willebrand disease (VWD) aims to restore the hemostatic function conferred by von Willebrand factor (VW …
127 results